Alpha-melanocyte-stimulating hormone protects against renal injury after ischemia in mice and rats
H Chiao, Y Kohda, P McLeroy, L Craig, I Housini, R A Star, H Chiao, Y Kohda, P McLeroy, L Craig, I Housini, R A Star
Abstract
Reperfusion after ischemia induces cytokines, chemoattractant chemokines, adhesion molecules, and nitric oxide (NO). The resultant neutrophil adherence and NO potentiates renal injury. alpha-Melanocyte-stimulating hormone (alpha-MSH) is a potent anti-inflammatory agent that inhibits neutrophil migration and production of neutrophil chemokines and NO. Since neutrophils and NO promote renal ischemic injury, we sought to determine if alpha-MSH inhibits renal injury in a model of bilateral renal ischemia. alpha-MSH significantly reduced ischemia-induced renal damage, measured by changes in renal histology and plasma blood urea nitrogen and creatinine in mice. alpha-MSH significantly decreased tubule necrosis, neutrophil plugging, and capillary congestion. Delay of alpha-MSH treatment for 6 h after ischemia also significantly inhibited renal damage. alpha-MSH also significantly inhibited ischemic damage in rats. To begin to determine the mechanism of action of alpha-MSH, we measured its effects on mediators of neutrophil trafficking and induction of the inducible isoform of NO synthase-II. alpha-MSH inhibited ischemia-induced increases in mRNA for the murine neutrophil chemokine KC/IL-8. alpha-MSH also inhibited induction of mRNA for the adhesion molecule ICAM-1, which is known to be critical in renal ischemic injury. alpha-MSH inhibited nitration of kidney proteins and induction of NO synthase-II. We conclude: (a) alpha-MSH protects against renal ischemia/reperfusion injury; and (b) it may act, in part, by inhibiting the maladaptive activation of genes that cause neutrophil activation and adhesion, and induction of NO synthase.
References
- Transplantation. 1995 Apr 15;59(7):962-8
- Ann N Y Acad Sci. 1994 Nov 25;741:137-48
- Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):8016-20
- Neuroimmunomodulation. 1994 Jan;1(1):28-32
- J Leukoc Biol. 1996 Feb;59(2):248-53
- J Clin Invest. 1996 Feb 15;97(4):1056-63
- J Clin Invest. 1996 May 1;97(9):2038-44
- J Clin Invest. 1996 May 15;97(10):2377-83
- N Engl J Med. 1996 May 30;334(22):1448-60
- Br J Surg. 1996 Feb;83(2):162-70
- Am J Physiol. 1996 Jun;270(6 Pt 2):F971-7
- Peptides. 1996;17(4):675-9
- Psychopharmacology (Berl). 1977 Dec 19;55(2):165-72
- Pharmacol Biochem Behav. 1978 Aug;9(2):207-12
- Anal Biochem. 1987 Apr;162(1):156-9
- Am J Physiol. 1989 May;256(5 Pt 2):F794-802
- Kidney Int. 1989 Oct;36(4):555-61
- Proc Natl Acad Sci U S A. 1991 Jul 15;88(14):6368-71
- Am J Physiol. 1991 Dec;261(6 Pt 2):F1095-101
- Science. 1992 Aug 28;257(5074):1248-51
- Virchows Arch B Cell Pathol Incl Mol Pathol. 1992;62(4):237-43
- Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):11876-80
- Endocr Rev. 1993 Oct;14(5):564-76
- Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):812-6
- Am J Physiol. 1994 Jan;266(1 Pt 2):F129-34
- Proc Natl Acad Sci U S A. 1994 Mar 1;91(5):1691-5
- Biol Chem Hoppe Seyler. 1994 Feb;375(2):81-8
- Am J Physiol. 1994 Jun;266(6 Pt 2):F949-56
- N Engl J Med. 1994 Nov 17;331(20):1338-42
- Biochem Biophys Res Commun. 1995 Jun 6;211(1):67-73
Source: PubMed